Quininib – 1 mg

Brand:
Cayman
CAS:
143816-42-6
Storage:
-20
UN-No:
Non-Hazardous - /

Quininib is an antagonist of the cysteinyl leukotriene 1 (CysLT1) and CysLT2 receptors (IC50s = 1.4 and 52 µM, respectively).{49221} It inhibits tubule formation in HMEC-1 cells when used at concentrations of 3.16 and 10 µM and inhibits sprout formation in isolated mouse aortic rings in an ex vivo model of angiogenesis when used at 10 µM. Quininib (3 µM) decreases angiogenesis in an oxygen-induced retinopathy mouse model of ocular angiogenesis, preventing revascularization when used at concentrations of 0.5 and 3 µM, as well as increasing neovascularization and vascular density when used at 3 µM. It reduces tumor growth and inhibits angiogenesis in an HT-29 colorectal cancer mouse xenograft model when administered at a dose of 50 mg/kg every three days.{49222}  

 

Available on backorder

SKU: 19838 - Category:

Description

A CysLT1 and CysLT2 receptor antagonist (IC50s = 1.4 and 52 µM, respectively); inhibits tubule formation in HMEC-1 cells at 3.16 and 10 µM; inhibits sprout formation in isolated mouse aortic rings at 10 µM; decreases angiogenesis in an oxygen-induced retinopathy mouse model of ocular angiogenesis, preventing revascularization at 0.5 and 3 µM, as well as increasing neovascularization and vascular density at 3 µM; reduces tumor growth and inhibits angiogenesis in an HT-29 colorectal cancer mouse xenograft model at 50 mg/kg every three days,


Formal name: 2-[(1E)-2-(2-quinolinyl)ethenyl]-phenol

Synonyms: 

Molecular weight: 247.3

CAS: 143816-42-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer|Angiogenesis||Research Area|Cell Biology|Cytoskeleton & Motor Proteins